| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0049-0172(95)80031-X |
| P698 | PubMed publication ID | 8650589 |
| P2093 | author name string | K Aho | |
| H A Isomäki | |||
| R A Myllykangas-Luosujärvi | |||
| P2860 | cites work | Length of life and cause of death in rheumatoid arthritis | Q73268669 |
| The general management of rheumatoid arthritis | Q80361996 | ||
| Mortality in rheumatoid arthritis, particularly as regards drug use | Q93561870 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis | Q33556875 | ||
| Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications | Q33560395 | ||
| Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study | Q33561343 | ||
| Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients | Q33562682 | ||
| Extra-articular manifestations of rheumatoid arthritis: risk factors for serious gastrointestinal events | Q33565873 | ||
| Rheumatoid factor, chronic arthritis and mortality | Q33578403 | ||
| COURSE AND PROGNOSIS IN RHEUMATOID ARTHRITIS. A FURTHER REPORT. | Q33626235 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| Ten year mortality and causes of death in patients with rheumatoid arthritis | Q34485318 | ||
| Quantitative measures to assess, monitor and predict morbidity and mortality in rheumatoid arthritis | Q35998710 | ||
| Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years | Q40213181 | ||
| Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. | Q40910814 | ||
| Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine | Q41117952 | ||
| Factors influencing mortality in rheumatoid arthritis. | Q41361691 | ||
| Neoplasms of the immune system in rheumatoid arthritis. | Q41485197 | ||
| Long-term outcome of treating rheumatoid arthritis: results after 20 years | Q41913707 | ||
| Mortality from cancer in patients with rheumatoid arthritis | Q42684020 | ||
| Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. | Q43616578 | ||
| Increased Mortality Among Persons with Rheumatoid Arthritis, But Where RA Does Not Appear on Death Certificate:Eleven-Year Follow-Up of an Epidemiological Study | Q44204294 | ||
| Childhood and adult socioeconomic status as predictors of mortality in Finland | Q46603101 | ||
| The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality | Q50592760 | ||
| Incidence of Cancer Among Patients With Rheumatoid Arthritis | Q57351660 | ||
| Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis | Q67429351 | ||
| Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 | ||
| Mortality among arthritics | Q67757844 | ||
| Long-term effects of treating rheumatoid arthritis | Q68094980 | ||
| Survival, prognosis, and causes of death in rheumatoid arthritis | Q69539302 | ||
| Cardiovascular mortality in patients with rheumatoid arthritis | Q69586053 | ||
| Mortality from renal diseases in Finland | Q70234129 | ||
| Increased mortality in rheumatoid arthritis | Q70383848 | ||
| Rheumatoid arthritis, aspirin, and gastrointestinal cancer | Q70543968 | ||
| Cause of death in rheumatoid arthritis | Q71349315 | ||
| Aspirin in the prevention of colorectal cancer | Q72075331 | ||
| Autoantibodies predicting death due to cardiovascular disease | Q72115583 | ||
| P433 | issue | 3 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 193-202 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Seminars in Arthritis and Rheumatism | Q15761553 |
| P1476 | title | Mortality in rheumatoid arthritis | |
| P478 | volume | 25 |
| Q51787678 | Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. |
| Q35954490 | All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists |
| Q33937792 | Assessing physical activity in persons with rheumatoid arthritis using accelerometry |
| Q37179297 | Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis |
| Q35553376 | Atherosclerotic cardiovascular disease in rheumatoid arthritis |
| Q33806651 | Cardiovascular morbidity and mortality in rheumatoid arthritis |
| Q33579147 | Clinical significance of antibodies against oxidised low density lipoprotein in early RA. |
| Q41377163 | Compliance in rheumatoid arthritis and the role of formal patient education |
| Q58484358 | Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: Relationship to systematic vasculitis and microvascular capillaroscopic abnormalities |
| Q33911444 | Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis? |
| Q35547301 | Dyslipidemia and rheumatoid arthritis |
| Q41757851 | Epidemiology of rheumatoid arthritis in Finland |
| Q34744649 | High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review. |
| Q34712199 | Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations |
| Q34305036 | Infections in systemic lupus erythematosus and rheumatoid arthritis. |
| Q34990100 | Infections in the immunocompromised rheumatologic patient |
| Q79319433 | Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy |
| Q35551023 | Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis |
| Q36291405 | No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population |
| Q35549071 | No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset |
| Q33438685 | Objective assessment of abnormal gait in patients with rheumatoid arthritis using a smartphone |
| Q37106758 | Pharmacotherapy options in rheumatoid arthritis |
| Q28192599 | Relative risk of cardiovascular events in patients with rheumatoid arthritis |
| Q44770173 | Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan |
| Q34962868 | Rheumatoid arthritis in women: still associated with an increased mortality. |
| Q33722916 | Screening for cancer in the patient with rheumatic disease |
| Q28165707 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program |
| Q34804676 | The demographics of chronic pain management |
| Q34275961 | The epidemiology of rheumatoid arthritis |
| Q33547329 | The role of endothelial function and its assessment in rheumatoid arthritis. |
| Q28241360 | Tocilizumab: a review of its use in the management of rheumatoid arthritis |
| Q46605378 | Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis. |
| Q36117792 | Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis |
Search more.